Intraoperative Considerations in a Patient on Intravenous Epoprostenol Undergoing Minimally Invasive Cardiac Surgery

Christina M Tull; Anand M Abraham; John W MacArthur; Matthew W Vanneman; T Robert Feng

doi:10.1053/j.jvca.2022.04.021

Intraoperative Considerations in a Patient on Intravenous Epoprostenol Undergoing Minimally Invasive Cardiac Surgery

J Cardiothorac Vasc Anesth. 2022 Aug;36(8 Pt A):2600-2605. doi: 10.1053/j.jvca.2022.04.021. Epub 2022 Apr 22.

Authors

Christina M Tull¹, Anand M Abraham¹, John W MacArthur², Matthew W Vanneman¹, T Robert Feng³

Affiliations

¹ Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University, Stanford, CA.
² Department of Cardiothoracic Surgery, Stanford University, Stanford, CA.
³ Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University, Stanford, CA. Electronic address: trfeng@stanford.edu.

PMID: 35644744
DOI: 10.1053/j.jvca.2022.04.021

No abstract available

Keywords: Intraoperative management of intravenous epoprostenol; intravenous prostacyclin; minimally-invasive cardiac surgery; pulmonary hypertension; side effects of IV epoprostenol; thoracotomy; ventilation/perfusion mismatch.

Publication types

Case Reports

MeSH terms

Antihypertensive Agents / therapeutic use
Cardiac Surgical Procedures*
Epoprostenol
Heart
Humans
Hypertension, Pulmonary* / drug therapy
Infusions, Intravenous

Substances

Antihypertensive Agents
Epoprostenol